News and Announcements
Novogen Edison Investment Research Report
- Published May 23, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Novegen (ASX: NRT) is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. Headquartered in Sydney, Australia, Novogen collaborates with leading scientists, clinicians, and investors around the world. Novogen’s recent market updates presented mixed news for investors.
KEY TAKEAWAYS:
- Recruitment in the Cantrixil Phase I is underway and preparations for the Phase II trial.
- Mixed data from preclinical studies have seen development terminated for Anisina, which had been expected to enter the clinic in H217.
- While the termination of Anisina is disappointing, it is encouraging to see that management is taking a disciplined approach to assessing pipeline products.
- Now valued, Novogen is between A$86m (A$0.18/share) and A$146m (A$0.30/share) under two different development scenarios for GDC-0084.
- Major milestones anticipated in 2017 include initiation of a Phase II trial of GDC-0084 and full enrolment in the Cantrixil Phase I.